In the past week, MLYS stock has gone up by 7.90%, with a monthly gain of 50.68% and a quarterly surge of 26.79%. The volatility ratio for the week is 7.37%, and the volatility levels for the last 30 days are 10.17% for Mineralys Therapeutics Inc The simple moving average for the past 20 days is 37.22% for MLYS’s stock, with a 27.56% simple moving average for the past 200 days.
Is It Worth Investing in Mineralys Therapeutics Inc (NASDAQ: MLYS) Right Now?
The stock has a 36-month beta value of 0.19. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MLYS is 31.01M, and at present, short sellers hold a 6.49% of that float. On March 19, 2025, the average trading volume of MLYS was 727.33K shares.
MLYS) stock’s latest price update
The stock of Mineralys Therapeutics Inc (NASDAQ: MLYS) has increased by 8.51 when compared to last closing price of 14.22.Despite this, the company has seen a gain of 7.90% in its stock price over the last five trading days. globenewswire.com reported 2025-03-18 that RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price of $13.50 per share pursuant to the exercise in full of the underwriters’ option to purchase additional shares in connection with Mineralys’ recently completed public offering. After giving effect to the sale of these additional shares, the aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $201.2 million. All of the securities sold in the offering were sold by Mineralys.
Analysts’ Opinion of MLYS
Many brokerage firms have already submitted their reports for MLYS stocks, with H.C. Wainwright repeating the rating for MLYS by listing it as a “Buy.” The predicted price for MLYS in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on July 10, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see MLYS reach a price target of $30. The rating they have provided for MLYS stocks is “Buy” according to the report published on April 02nd, 2024.
Wells Fargo gave a rating of “Overweight” to MLYS, setting the target price at $27 in the report published on March 07th of the previous year.
MLYS Trading at 44.78% from the 50-Day Moving Average
After a stumble in the market that brought MLYS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.64% of loss for the given period.
Volatility was left at 10.17%, however, over the last 30 days, the volatility rate increased by 7.37%, as shares surge +60.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.96% upper at present.
During the last 5 trading sessions, MLYS rose by +7.90%, which changed the moving average for the period of 200-days by +25.35% in comparison to the 20-day moving average, which settled at $11.24. In addition, Mineralys Therapeutics Inc saw 25.35% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MLYS starting from Samsara BioCapital GP, LLC, who purchase 600,000 shares at the price of $13.50 back on Mar 13 ’25. After this action, Samsara BioCapital GP, LLC now owns 5,674,916 shares of Mineralys Therapeutics Inc, valued at $8,100,000 using the latest closing price.
AKKARAJU SRINIVAS, the Director of Mineralys Therapeutics Inc, purchase 600,000 shares at $13.50 during a trade that took place back on Mar 13 ’25, which means that AKKARAJU SRINIVAS is holding 5,674,916 shares at $8,100,000 based on the most recent closing price.
Stock Fundamentals for MLYS
The total capital return value is set at -1.01. Equity return is now at value -82.24, with -77.72 for asset returns.
Currently, EBITDA for the company is -192.4 million with net debt to EBITDA at 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.02.
Conclusion
To sum up, Mineralys Therapeutics Inc (MLYS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
